New pill could let Sun-Sensitive patients enjoy the outdoors
NCT ID NCT06910358
First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 9 times
Summary
This Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. The study measures pain-free sun exposure and changes in blood porphyrin levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bitopertin
- What this could lead to
- If it works, this could provide a daily pill that allows people with EPP or XLP to spend more time in sunlight without pain.
- What could go wrong
- This is a Phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nantes - Hôtel Dieu, Service de dermatologie
Nantes, France, 44093, France
-
Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard
Paris, France, 75018, France
-
Charité - Universitätsmedizin Berlin, Institute of Allergology
Berlin, Germany, 12203, Germany
-
Children's Health Ireland (CHI)
Dublin, D12N512, Ireland
-
Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside
Dundee, Scotland, DD1 9SY, United Kingdom
-
Erasmus MC
Rotterdam, The Netherlands, 3015 GD, Netherlands
-
Guy's and St Thomas' NHS Foundation Trust
London, England, SE1 9RT, United Kingdom
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Clinic de Barcelona
Barcelona, Spain, 08036, Spain
-
Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS
Roma, 53-00144, Italy
-
Karolinska University Hospital
Stockholm, Sweden, 141 86, Sweden
-
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, 09116, Germany
-
Marvel Clinical Research
Huntington Beach, California, 92647, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
MetroBoston Clinical Partners
Boston, Massachusetts, 02135, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Photobiology Unit, Salford Royal Hospital
Salford, M6 8HD, United Kingdom
-
Remington-Davis Clinical Research
Columbus, Ohio, 43215, United States
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
UZ Leuven
Leuven, 3000, Belgium
-
University of Alberta
Edmonton, Alberta, T6G 2R3, Canada
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33146, United States
-
University of Texas Medical Branch
Galveston, Texas, 77550, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Wake Forest University
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily pill douse the Sun's pain for people with EPP?
- New hope for rare sun allergy: bitopertin offered to patients with no options
- New study aims to unlock mysteries of rare sun allergy disorders
- New drug aims to let sunlight-sensitive patients enjoy the sun longer
- New pill could let EPP patients enjoy the sun without pain